Zongertinib (Hernexeos) Approved for First-Line Treatment of HER2-Positive Lung Cancer

On 26 February 2026, for adult patients with unresectable or metastatic nonsquamous non–small-cell lung cancer (NSCLC) harboring HER2 (ERBB2) tyrosine kinase domain mutations, the FDA granted zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.) accelerated approval as first-line treatment.

The full scientific report of the Beamion LUNG-1 study that led to this FDA approval was published in NEJM on 15 April 2026.

HER2-Mutant Lung Cancer: A Small but Critical Window

The HER2 (ERBB2) gene encodes a receptor tyrosine kinase protein on the cell surface that transmits growth signals into the cell. In breast cancer, HER2 overexpression or amplification has long been a known mechanism successfully addressed with targeted therapies. The picture is somewhat different in lung cancer: what is involved here is a HER2 mutation — a point change that makes the gene permanently active. This difference explains why directly transferring HER2 approaches that work in breast cancer to lung cancer is often insufficient.

HER2 mutations occur in approximately 2–4% of non–small-cell lung cancers. Although this proportion may seem small, the absolute number of patients is substantial because lung cancer is the most common cancer worldwide. For many years, these patients were directed toward standard chemotherapy and immunotherapy protocols because they had no first-line option directly targeting this feature. Zongertinib was designed to close this gap.

Why Is Zongertinib Different? Why Selectivity Matters So Much

Zongertinib is an oral, irreversible tyrosine kinase inhibitor (TKI — tyrosine kinase inhibitor). At the molecular level, it selectively blocks mutant HER2 while largely sparing wild-type EGFR (epidermal growth factor receptor — its normal, nonmutated form). This selectivity is critical.

Previous-generation pan-HER inhibitors suppressed both mutant HER2 and EGFR. Although this appeared powerful in theory, in practice it caused serious EGFR-related toxicities, particularly severe diarrhea and skin rash, and these adverse effects could require dose reduction or treatment discontinuation. Zongertinib breaks this pattern by offering selectivity that attacks only the target.

Two Approvals, One Major Step

Zongertinib’s FDA approval journey illustrates how quickly efficacy data can prompt a regulatory response.

This second approval moves zongertinib from being merely a salvage option in HER2-mutant lung cancer to the starting point of treatment planning. Knowing the molecular profile at diagnosis, before any treatment has been given, now directly changes the treatment decision.

NEJM Data: The First-Line Cohort of Beamion LUNG-1

The Beamion LUNG-1 study (NCT04886804) evaluated zongertinib at 120 mg daily in previously untreated patients with advanced/metastatic HER2-mutant nonsquamous NSCLC. The first-line cohort (Cohort 2) included 74 patients. The results were striking in both speed and durability.

To make the clinical significance of these figures tangible, some perspective is needed: response rates with standard chemotherapy regimens in HER2-mutant lung cancer generally fall in the 30–40% range, and responses are much shorter. A 76% response rate means measurable tumor shrinkage in approximately three out of every four patients. The median response duration of 15.2 months indicates that this response is not transient and that zongertinib can maintain tumor control for a long time.

The Neuro-Oncological Dimension: A 47% Intracranial Response in Active Brain Metastases

Perhaps the part of Beamion LUNG-1 that draws the most attention from clinicians is the data from Cohort 4, which separately evaluated patients with active brain metastases. This cohort of 30 patients directly measured zongertinib’s effect on the central nervous system.

Brain metastasis is one of the most challenging stages in the course of lung cancer. Many systemic agents cannot adequately cross the blood–brain barrier (BBB); brain lesions therefore often remain a site of disease progression even when systemic treatment is producing a response elsewhere. The 47% intracranial response rate shows that active brain metastases can regress in nearly one in two patients. This is an efficacy claim based on direct clinical data, beyond the level of “it may theoretically penetrate the brain.”

Adverse Effects: Frequent but Mostly Manageable

A common mistake when assessing the safety profile of targeted therapies is to portray these drugs as “free of adverse effects.” An honest framework is needed for zongertinib as well.

This table should be read as follows: the rate of adverse events (side effects) of any severity appears to be 99%, which may raise concerns. However, the figure with the greatest clinical significance is that the rate of grade 3 or higher treatment-related adverse events was only 19% — meaning that approximately 1 in 5 patients experienced a treatment-related problem that could be considered serious. The rate was even lower in the cohort with brain metastases: %17. In the investigators’ assessment, adverse effects were mostly low grade and manageable. The EGFR-sparing effect of HER2 selectivity substantially reduces the severe diarrhea and skin toxicities seen with previous-generation pan-HER inhibitors.

How Do These Data Change Practice?

This article was created using various editorial tools, including artificial intelligence, as part of the process. It was reviewed by human editors before publication.